Starting Patients on Peptides: A Clinical Framework for the First 90 Days

Introducing peptides into patient care works the same way as introducing any new clinical service: select the right first patients, document consent properly, start from established protocols instead of improvising, and follow up on a schedule. Practices that follow those four steps build a defensible, repeatable program. Practices that skip them end up with scattered one-time sales and no clinical story behind them. Here is the framework, step by step.

Which Patients Should a Practice Start With?

Start with patients who are already leaning in. Three groups consistently make the best first cohort:

• Current and former GLP-1 patients. They already trust the peptide category because their weight-loss medication is one. They are also the group most likely to ask what else peptides can do, across the peptide categories patients are already asking about.
• Recovery patients. Post-surgical patients, aesthetic-procedure patients, and athletes have an immediate, concrete use for recovery support, which makes the conversation short and natural.
• Longevity-focused patients. These patients seek the practice out, ask informed questions, and tend to stay on programs long term.

One group deserves special mention: needle-averse patients. Historically they were excluded from peptide therapy entirely. With enteric-coated oral capsules and topical serums, they are now eligible, and they are often the most grateful cohort in the program.

What Does Responsible Consent and Documentation Look Like?

It starts with being accurate about what each product is. Peptides span several regulatory categories: some are FDA-approved prescription drugs, others are Research Use Only compounds. A responsible program labels everything accurately and documents that the patient understood it. Regulatory transparency over regulatory theater.

In practice, that means four things happen before the first dose:

• Informed consent is signed. Use a consent form written for the specific product category, not a generic supplement waiver.
• The product category is documented. The chart should reflect exactly what the patient is taking and under what labeling.
• Verification is on record. Every AgeREcode vial carries a QR code for independent third-party verification through Chromate.org. Logging it takes seconds and strengthens the record. Knowing how to evaluate a peptide supplier is part of the same discipline.
• Staff follow a written SOP. Consistent process beats individual judgment calls at the front desk.

AgeREcode provides customizable informed consent forms, patient handouts, treatment logs, and staff SOPs, so none of this has to be built from scratch.

How Do You Choose the First Protocols?

Do not improvise. Start from established protocols and adjust from there.

• Lead with metabolic and recovery. These are the categories with existing patient demand, which makes them the easiest conversations and the fastest wins for staff confidence.
• Pull from the Protocol Portal. The 200-plus condition-specific protocols include dosing guides and contraindications, and the Clinical Operator's Manual covers patient education and program structure around them.
• Use pre-structured regimens. Protocols are built as real-world clinical programs, from one-week trials up to full 90-day patient regimens, so the practice is choosing between defined options rather than designing from a blank page.
• Start small on purpose. A one-week trial is a clinical decision as much as a sales tool: it establishes tolerance and compliance before the patient commits to a full protocol.

How Should Monitoring and Follow-Up Work?

On a schedule, set at the first visit. A workable cadence:

1. 1Baseline. Document goals, current medications, relevant history, and expectations. Set the review dates before the patient leaves.
2. 2Two-week check-in. Confirm tolerance and compliance. This can be a staff touchpoint rather than a provider visit.
3. 3Four-to-six-week visit. Review progress against the patient's stated goals and adjust the protocol if needed.
4. 490-day review. The formal decision point: continue, adjust, or add a complementary product where the patient has a need in a second category.

Two principles hold the cadence together. First, track patient-reported outcomes against the goals set at baseline, because that is the honest measure of whether the program is working for that patient. Second, keep expectations grounded: individual results vary, and the protocols are built around defined evaluation windows rather than promises.

What Should Staff Be Trained to Say?

The same thing, every time. Inconsistent answers at the front desk undermine an otherwise well-run program. Staff should be fluent on the handful of questions every patient asks:

• "Is this FDA approved?" Staff give the accurate category answer for the specific product and hand the patient the written material that says the same thing.
• "Do I have to inject it?" No. The core line is oral capsules and topical serums.
• "How long until I notice something?" The protocol sets the evaluation window, and the provider reviews progress at the scheduled visits.
• "Is this safe with my medications?" This one always goes to the provider. Staff route it, they do not answer it.

The on-demand clinician training video library and the patient handouts exist precisely so that everyone in the building gives the same answer. Train once, then let the materials keep everyone aligned.